Apr 18, 2018 7:00 am EDT Heat Biologics Announces Upcoming Milestones Following Positive Interim Phase 2 Results for HS-110
Mar 26, 2018 7:00 am EDT Heat Biologics Reports Positive Data to Further Support the Mechanism of Action for its Proprietary T-Cell Activation Platform
Mar 19, 2018 6:00 am EDT Heat Biologics and Its Pelican Therapeutics Subsidiary Appoint Anthony Tolcher, M.D., FRCPC, FACP to their Scientific Advisory Boards
Mar 14, 2018 7:00 am EDT Heat Biologics to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium
Mar 13, 2018 7:00 am EDT Heat Biologics to Present at the BIO-Europe Spring Conference, March 12-14, 2018, in Amsterdam
Feb 28, 2018 6:00 am EST Heat Biologics Announces Positive Interim Data from its Phase 2 Clinical Trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
Feb 26, 2018 7:00 am EST UPDATE: Heat Biologics to Host Analyst and Investor Event February 28, 2018, to Present Results from its Phase 2 Lung Cancer Study